CN Patent

CN108472252A — 赖诺普利制剂

Assigned to Silvergate Pharmaceuticals Inc · Expires 2018-08-31 · 8y expired

What this patent protects

本文提供了稳定的赖诺普利口服液体制剂。本文还提供了使用赖诺普利口服液体制剂治疗包括高血压、心力衰竭和急性心肌梗死在内的某些疾病的方法。

USPTO Abstract

本文提供了稳定的赖诺普利口服液体制剂。本文还提供了使用赖诺普利口服液体制剂治疗包括高血压、心力衰竭和急性心肌梗死在内的某些疾病的方法。

Drugs covered by this patent

Patent Metadata

Patent number
CN108472252A
Jurisdiction
CN
Classification
—
Expires
2018-08-31
Drug substance claim
No
Drug product claim
No
Assignee
Silvergate Pharmaceuticals Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.